Blood Chemistry Study in Mild ARDS
Part of Lungs & breathing clinical trials.
This study uses a special blood test (called NMR metabolomics) to understand how your body's chemistry changes in the early stages of mild ARDS. It may help find better ways to treat this serious lung condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have been diagnosed with mild ARDS (acute respiratory distress syndrome) that started in the last 3 days.
- Doctors expect you to live more than 3 days.
- Your family agrees to your participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for patients in the ICU with ARDS (a severe lung condition). It looks at biomarkers (special substances in your blood) to help understand different types of ARDS. You do not receive any treatment, but you help researchers learn more about the disease.
This study looks at blood and sputum samples from people with ARDS (a severe lung condition) to find what affects their recovery. It might help doctors better understand how to treat ARDS in the future.
This study examines lung fluid samples and imaging scans from patients on breathing machines to better understand acute respiratory distress syndrome (ARDS), a serious lung condition. Researchers hope this will help doctors diagnose and treat ARDS more effectively in the future.
This trial studies how immune cells in the lungs and gut microbes (your microbiome) change during ARDS and how these changes relate to your outcomes. It may help researchers better predict and treat ARDS by learning what’s going on in the lungs and body systems.
This trial observes the symptoms, treatments, and recovery of patients with acute respiratory distress syndrome (ARDS), a serious lung condition. It aims to learn more about how different types of breathing support affect outcomes.
This study is testing whether certain proteins in the blood (sRAGE, CC16, and Syndecan-1) can help predict if patients with severe chest trauma will develop a serious lung condition called ARDS or have a higher risk of death. By measuring these proteins early, doctors might be able to identify high-risk patients sooner and provide more targeted care.
Hear when a new ARDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.